GLP-1 receptor agonist medications — semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), and newer agents — were developed for type 2 diabetes and are now also approved for obesity and cardiovascular risk reduction. Four significant research findings published in June 2026 suggest these drugs may affect far more than the conditions they were designed to treat.
Together, the findings paint a picture of a drug class with broad systemic effects, some of which offer exciting potential benefits and others that require active clinical management. Here is what each found, and what it means if you or a family member is taking these medications.
Finding 1: 30 Percent Lower Breast Cancer Odds in GLP-1 Users
A study from Penn Medicine, presented at the 2026 ASCO Annual Meeting and published in JCO Oncology Practice, analyzed health records from more than 111,000 women with obesity or type 2 diabetes and found that those who used GLP-1 receptor agonists had approximately 30 percent lower odds of developing breast cancer compared to matched controls who did not use these drugs.
The finding is observational and cannot prove causation — it is possible that women who used GLP-1 drugs differed in other important ways from those who did not. However, the biological mechanism is plausible: obesity is a well-established risk factor for postmenopausal breast cancer, and GLP-1 drugs that reduce weight might reduce risk through adiposity pathways. Additionally, reporting on the study notes that a second, smaller study of high-risk women found a similar but more modest reduction, adding to evidence that GLP-1 receptors may create direct antitumor effects beyond weight reduction alone.
What this means for patients: This is preliminary evidence of a potential cancer-protective benefit — not an approved indication or a treatment. Women on GLP-1 drugs should continue recommended breast cancer screening on schedule, but this finding provides additional context about potential systemic benefits of the drug class.
Finding 2: GLP-1 Drugs Weakened the Impulsivity-to-Violence Link by 62 Percent
A study from Rutgers University, published in June 2026 in the journal Criminology, analyzed survey data from 7,521 U.S. adults, focusing on 821 individuals who had used a GLP-1 medication. The study found that among current GLP-1 users, the well-established link between impulsivity and violent behavior was approximately 62 percent weaker than among former users, and the link between alcohol use and violence was about 52 percent weaker.
The biological basis for this finding relates to GLP-1 receptors in the brain, particularly in areas associated with impulse control, reward processing, and emotional regulation. As lead author Daniel Semenza put it in coverage of the study, the medications appear to function somewhat like cognitive behavioral therapy, weakening the pathway from impulse to action rather than eliminating impulsivity itself.
What this means for patients: This is very early, observational, and cross-sectional research. It does not suggest GLP-1 drugs should be used as a psychiatric or violence prevention tool. But it contributes to a growing body of evidence that GLP-1 receptors in the brain affect behavior in ways that extend well beyond hunger regulation.
Finding 3: GLP-1 Drugs Appear Protective Against Bone Fractures Despite Weight Loss
One of the concerns about significant weight loss from any cause — including GLP-1 drug use — has been the potential for loss of bone mass. Weight loss typically involves some loss of lean body mass, and reduced mechanical loading on bones can reduce bone density over time.
A June 2026 retrospective cohort study from Stanford University, presented at ENDO 2026, the Endocrine Society's annual meeting, found that in people with type 2 diabetes, semaglutide use was associated with a 15 percent reduction in fracture incidence compared with other GLP-1 receptor agonists and alternative weight-loss therapies, even though semaglutide produced greater weight loss. The proposed mechanism, according to coverage of the findings, is that semaglutide may have direct bone-protective effects that partially offset the mechanical unloading effect of weight reduction.
What this means for patients: Bone health monitoring remains important for anyone losing significant weight — through GLP-1 drugs or any other means — especially postmenopausal women and older adults. But this finding provides some reassurance that the fracture risk concern may be smaller than previously anticipated for semaglutide specifically, though the study's own authors note prospective studies are still needed to confirm the result.
Finding 4: GLP-1 Drug Users Show Significantly Less Daily Physical Activity — a Clinical Management Concern
A study using Fitbit wearable data linked to electronic health records from the NIH's All of Us Research Program, also presented at ENDO 2026, found that adults with obesity who began GLP-1 therapy saw daily steps drop by 560 on average and moderate-to-vigorous physical activity decline by nearly six minutes per day — changes the researchers described as statistically significant.
This finding is the most immediately actionable for clinicians. Lead researcher Sajana Maharjan noted in coverage of the study that prior research relying on self-reported activity may have missed this pattern, and that the wearable data gave investigators an objective answer to whether patients actually become more active as they lose weight — they do not, on average.
The clinical concern: physical inactivity has independent negative health consequences, including cardiovascular disease risk, independent of body weight. If GLP-1-induced weight loss comes at the cost of significant reductions in physical activity, some of the cardiovascular benefit of weight loss may be offset, and the loss of lean muscle mass associated with these drugs may be compounded.
What this means for patients: This finding underscores the importance of structured exercise counseling as part of any GLP-1 drug regimen. Patients starting semaglutide or tirzepatide should work with their physician or a physical therapist to set and maintain physical activity targets, and should not let the medication's hunger-suppressing effects lead them to become more sedentary.
What the Evidence Shows — and What It Does Not
MedicalDaily Evidence Check (collective)
- All four findings are observational studies or analyses of real-world data — not randomized controlled trials
- None proves causation; each shows associations that require further study
- The breast cancer, violence, and bone fracture findings are potentially encouraging and merit further study, including in randomized trials
- The physical activity finding is a clinical management concern that requires immediate attention in clinical practice
- None of these findings changes the current approved indications for GLP-1 drugs or the existing evidence base for their use
What Doctors and Experts Say
The emerging evidence on GLP-1 drugs' broad systemic effects has generated significant interest in the endocrinology and internal medicine communities. The convergence of findings affecting the brain, the immune system, bone metabolism, and carcinogenesis reflects the widespread distribution of GLP-1 receptors throughout the body, a distribution that was underappreciated when these drugs were first developed for glucose lowering.
Endocrinologists and obesity medicine specialists who reviewed the collective June 2026 findings have noted that the physical activity reduction finding deserves the most immediate clinical attention, as it represents an actionable management consideration for current patients.
What You Can Do Now
- If you are taking a GLP-1 drug, discuss physical activity goals with your physician at your next visit. Do not let appetite suppression become an inadvertent reason to move less.
- Consider working with a physical therapist or certified exercise specialist as part of your GLP-1 drug regimen, particularly if you are experiencing fatigue or decreased motivation for exercise.
- Follow your physician's bone health monitoring recommendations if you are a postmenopausal woman or older adult experiencing significant weight loss.
- Do not start or stop GLP-1 medications based on any of the emerging research findings — discuss changes with your physician.
What Happens Next
Each of the four findings will require larger, prospective, ideally randomized studies to establish more definitive evidence of causation. The physical activity finding may generate the fastest clinical response, as it is actionable in existing patients right now. The breast cancer finding may prompt researchers to investigate GLP-1 receptor expression in breast tissue more systematically. MedicalDaily will report on follow-up studies and any clinical guideline changes that incorporate these findings.
The Bottom Line
Four independent research findings published in June 2026 all point in the same direction: GLP-1 drugs affect the body well beyond the glucose and weight pathways for which they were designed. The potential breast cancer, bone, and impulse control findings are intriguing early signals worth monitoring. The physical activity reduction is a clinical management concern that deserves immediate attention from every clinician prescribing these drugs. GLP-1 medications are effective and increasingly widely used — understanding their full systemic effects is becoming essential.
